Psyence Biomedical (NASDAQ:PBM) Stock Price Up 1% – Should You Buy?

Posted by ABMN Staff on May 23rd, 2026

Psyence Biomedical Ltd. (NASDAQ:PBM – Get Free Report)’s stock price shot up 1% on Friday . The stock traded as high as $4.44 and last traded at $4.10. 76,765 shares were traded during trading, a decline of 75% from the average session volume of 309,516 shares. The stock had previously closed at $4.06.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Psyence Biomedical in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Read Our Latest Stock Report on Psyence Biomedical

Psyence Biomedical Price Performance

The firm has a market capitalization of $4.18 million, a P/E ratio of 0.16 and a beta of 1.78. The company has a fifty day moving average of $4.38 and a 200 day moving average of $6.13.

Institutional Investors Weigh In On Psyence Biomedical

A hedge fund recently bought a new stake in Psyence Biomedical stock. Virtu Financial LLC bought a new position in shares of Psyence Biomedical Ltd. (NASDAQ:PBM – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 10,325 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.55% of Psyence Biomedical as of its most recent SEC filing. Hedge funds and other institutional investors own 77.44% of the company’s stock.

Psyence Biomedical Company Profile

(Get Free Report)

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.